Compare Moderna, Inc. (MRNA) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs PPG Industries, Inc. — how do they compare? Moderna, Inc. trades at $220.73 (market cap $78.65B), while PPG Industries, Inc. trades at $104.88 (market cap $23.44B). The key difference: Moderna, Inc. is far larger — about 3.4× PPG Industries, Inc.'s market cap, and PPG Industries, Inc. pays a 2.81% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and PPG Industries, Inc. for 68 Days on average.
| MRNA | PPG | |
|---|---|---|
Market Cap | $78.65B | $23.44B |
Volume | 37,373,437 | 2,064,777 |
Sector | Health | Basic Materials |
52-Week High | $203.46 | $131.56 |
52-Week Low | $22.36 | $94.34 |
Typical Hold Time | 59 Days | 68 Days |
Enterprise Value | $74.80B | $29.31B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
PPG Industries trades at $104.79, down 0.28% for the day, with a bearish technical signal from moving averages and neutral oscillators. The company reported 2025 revenue of $15.88 billion and net income of $1.58 billion, with a P/E ratio of 15.13. Recent earnings showed mixed results, missing in Q4 2025 and Q2 2026 but beating in Q1 2026. Analyst consensus is a Buy with a $130 price target, while recent news highlights margin pressures in the Automotive Refinish segment.
The outlook for PPG is cautiously optimistic, supported by strong profitability metrics like a 9.57% net income margin and 19.63% ROE, but risks include segment-specific weaknesses and macroeconomic headwinds. Upside potential exists if the company meets Q3 2026 earnings expectations and sustains cost-control measures, though investors should monitor auto refinish performance and global demand trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
